Are you a journalist? Please sign up here for our press releases
Subscribe to our monthly newsletter:
<p>
A new era is dawning in the battle against cancer. In the more than 30 years that have elapsed since U.S. President Richard Nixon “declared war” on cancer in 1971, scientists have made gigantic strides in charting the course of this affliction. We now know that cancer is a disease of damaged genes. We also know that it develops in multiple stages and takes many years, even decades, to unfold. We have learned moreover that there are hundreds of different cancers, each caused by a specific set of genetic defects, which is one of the major reasons that malignancy is so difficult to treat.</p>
<p>
</p>
<p>
Thanks to this new understanding, the entire management of cancer promises to change. Genetic testing will make it possible to identify groups of people who are most prone to develop cancer and who must therefore take preventive measures. Non-invasive DNA analysis and improved imaging techniques will allow physicians to detect and diagnose cancer earlier. Finally, therapies will become more selective and precise. Rather than destroying tissues in bulldozer fashion as do the traditional chemotherapy and radiation treatments, they will serve as finer tools, carving out the tumor while sparing healthy tissues. It may even become possible to design tailor-made treatments to suit the patient’s individual traits and genetic profile.</p>
<p>
</p>
<p>
Weizmann scientists were the first to clone p53, a gene involved in more than half of all human cancers; basic research conducted at the Institute provided the foundation for the development of Glivec®, the first in the upcoming generation of molecular drugs; and a number of cancer therapies developed at Weizmann are currently being tested in clinical trials.</p>
Research on a Potential Cancer Vaccine
A synthetic vaccine produced at the Weizmann Institute stopped lung cancer from spreading in mice and offers hope as a potential treatment form human cancers.
One of the major problems in cancer is that the immune system does not react to tumors with sufficient vigor, eventually enabling the cancer to overrun the body. With this research, the scientists appear to have found a way to prompt a stronger response from the immune system.
Prof. Lea Eisenbach and her colleagues in the Institute's Immunology Department discovered that connexin-37, a protein normally present in lung cells, contains a mutation in cancerous cells. When they injected mice with the mutant protein, the animals' immune systems produced white blood cells known as cytotoxic T lymphocytes that attacked and killed the cancerous cells.
The scientists developed a synthetic vaccine from this compound and found that it not only protected mice with cancer from the further spread of tumors but reduced the number of existing tumors. In experiments, some of the vaccinated mice were still alive more than a year later, while untreated mice died after a month.
If developed for human cancer therapy in the future, such vaccines could be particularly useful for mopping up the tiny tumors that often remain after surgeons have removed the main growth.